Bakri Baloon
DeviceBakri Balloon Standard insertion and inflation as per hospital protocol following delivery.
NCT Number: NCT06996808
Postpartum hemorrhage (PPH) remains one of the leading causes of maternal morbidity and mortality worldwide, particularly in low- and middle-income countries. It is defined as blood loss of more than 500 mL after vaginal delivery or more than 1000 mL after cesarean section, but severe PPH is typically identified when blood loss exceeds 1000 mL regardless of delivery mode. The initial management of PPH includes the administration of uterotonics such as oxytocin, methylergometrine, and tranexamic acid. However, a subset of patients remains unresponsive to medical therapy, necessitating second-line interventions to avoid escalation to invasive procedures such as uterine artery embolization or peripartum hysterectomy.
An intrauterine balloon tamponade device (Bakri©), is commonly used as a mechanical method to control uterine bleeding by exerting direct pressure on the uterine walls. Its use has been widely adopted and incorporated into international guidelines due to its relative ease of use and safety profile. Despite its effectiveness, the failure rate of Bakri balloon placement can range from 20% to 40%, especially in cases of coagulopathy or diffuse atony.
Gauzes with a chitosan-based hemostatic dressing (Celox PPH ©) , has been extensively used in trauma settings and is increasingly being explored for surgical and obstetric applications. Its mechanism involves promoting clot formation independent of the clotting cascade, making it potentially beneficial in patients with coagulopathies. Preliminary data and case reports suggest that Celox PPH© may be effective in controlling intrauterine bleeding when used as a packing material after vaginal or cesarean delivery, but no high-quality randomized controlled trial has yet compared it directly with standard interventions.
Given the clinical need for alternative second-line treatments for PPH unresponsive to medical therapy, this study proposes a head-to-head comparison of the Bakri balloon and Celox gauze. The findings will help inform evidence-based guidelines and may offer new strategies to reduce maternal transfusion requirements, prevent hysterectomy, and shorten hospital stays in patients experiencing severe PPH.
Trial opening soon.
Get Notified18 year and older
Female
Interventional
Not applicable
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Participants must meet all of the following criteria to be eligible for inclusion:
Exclusion criteria
Patients will be excluded if they meet any of the following conditions:
Bakri Balloon Standard insertion and inflation as per hospital protocol following delivery.
Celox gauze will be placed intrauterine according to manufacturer instructions, post-vaginal or cesarean delivery. Duration and removal will follow standardized clinical guidelines
Time frame: From enrollment to 24 hours after delivery
Materal hemoglobin levels will be assessd at diagnosis of Post partum hemorrage, 24 after delievry and at the discharge
Time frame: From enrollment to 24 hours after delivery
Time frame: From enrollment to one week after delivery
Need of performing hysterectomy
Time frame: From delivery up to 6 weeks postpartum
Time frame: From enrollment up to 6 weeks postpartum
Time frame: From enrollment to the firstday after delivery and at one week
needs of other surgical procedures (i.e, suture of uterine lacerations, uterine hemostatic suture(ì)
Contact information is provided by the study sponsor or research team.
University of Roma La Sapienza
Other
Intrauterine Balloon (Bakri©) Versus Uterine Tamponade With Chitosan Gauze (Celox PPH©) in the Management of Postpartum Hemorrhage Refractory to Medical Treatment: A Multicenter Randomized Controlled Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07688512
Dystocia, Elective Cesarean Section
View Trial DetailsNCT07636421
Blood Loss, Surgical, Cesarean Section
Buraidah, Al-Qassim Region, Saudi Arabia
View Trial DetailsNCT07609589
Dystocia, Female Urogenital Diseases and Pregnancy Complications
View Trial DetailsNCT07606846
Cesarean Section, Dystocia
View Trial Details